Workflow
上海皓元医药股份有限公司 关于2023年限制性股票激励计划 第二类限制性股票第二个归属期归属结果暨股份上市公告

Core Points - The company announced the results of the second vesting period for its 2023 restricted stock incentive plan, with 527,660 shares to be listed on August 6, 2025, representing 0.25% of the company's total share capital before vesting [2][3][4] Group 1: Stock Incentive Plan Details - The stock listing type is for equity incentive shares, with a total of 527,660 shares to be listed [2][3] - The decision-making process for the stock vesting was approved by the board and supervisory committee on June 26, 2023, and the plan was publicly disclosed on June 27, 2023 [4][5][6] - The number of individuals eligible for the stock vesting is 97, with the actual number of shares vesting being 527,660 [12][13] Group 2: Stock Listing and Capital Changes - The listing date for the vested shares is set for August 6, 2025, and the total share capital will increase from 211,571,033 shares to 212,098,693 shares [14][17] - The company received a total of RMB 11,904,009.60 from the 97 participants in the stock incentive plan, which includes an increase in share capital of RMB 527,660 [17] - The impact of the new shares on the company's financial report is minimal, with the diluted earnings per share remaining stable [18] Group 3: Convertible Bond Adjustments - The company announced an adjustment to the conversion price of its convertible bonds ("Hao Yuan Convertible Bonds") due to the completion of the stock vesting [19][20] - The conversion price was adjusted from RMB 40.59 to RMB 40.55 per share, effective from August 5, 2025 [23][26] - The adjustment was made in accordance with the company's regulations and relevant laws, ensuring the protection of bondholders' rights [24][25]